These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 32291401)

  • 21. Half-fluence photodynamic therapy in chronic central serous chorioretinopathy.
    Smretschnig E; Ansari-Shahrezaei S; Hagen S; Glittenberg C; Krebs I; Binder S
    Retina; 2013 Feb; 33(2):316-23. PubMed ID: 23314238
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of half-dose versus half-fluence versus standard photodynamic therapy in chronic central serous chorioretinopathy.
    Altinel MG; Kanra AY; Totuk OMG; Ardagil A; Kabadayi K
    Photodiagnosis Photodyn Ther; 2021 Mar; 33():102081. PubMed ID: 33157327
    [TBL] [Abstract][Full Text] [Related]  

  • 23. One-year choroidal thickness results after photodynamic therapy for central serous chorioretinopathy.
    Maruko I; Iida T; Sugano Y; Furuta M; Sekiryu T
    Retina; 2011 Oct; 31(9):1921-7. PubMed ID: 21878850
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term chorioretinal changes after photodynamic therapy for chronic central serous chorioretinopathy.
    Vasconcelos H; Marques I; Santos AR; Melo P; Pires I; Figueira J; de Abreu JF; Cachulo ML; Silva R
    Graefes Arch Clin Exp Ophthalmol; 2013 Jul; 251(7):1697-705. PubMed ID: 23389551
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term follow-up of chronic central serous chorioretinopathy after successful treatment with photodynamic therapy or micropulse laser.
    van Rijssen TJ; van Dijk EHC; Scholz P; Breukink MB; Dijkman G; Peters PJH; Tsonaka R; Keunen JEE; MacLaren RE; Hoyng CB; Downes SM; Fauser S; Boon CJF
    Acta Ophthalmol; 2021 Nov; 99(7):805-811. PubMed ID: 33565230
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of photodynamic therapy and navigated microsecond laser for chronic central serous chorioretinopathy.
    Ntomoka CG; Rajesh B; Muriithi GM; Goud A; Chhablani J
    Eye (Lond); 2018 Jun; 32(6):1079-1086. PubMed ID: 29429986
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of mineralocorticoid receptor antagonist for central serous chorioretinopathy: a meta-analysis.
    Zhang B; Chou Y; Zhao X; Yang J; Chen Y
    Int Ophthalmol; 2020 Nov; 40(11):2957-2967. PubMed ID: 32632615
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Choroidal Anatomic Alterations After Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: A Multicenter Study.
    Iovino C; Au A; Chhablani J; Parameswarappa DC; Rasheed MA; Cennamo G; Cennamo G; Montorio D; Ho AC; Xu D; Querques G; Borrelli E; Sacconi R; Pichi F; Woodstock E; Sadda SR; Corradetti G; Boon CJF; van Dijk EHC; Loewenstein A; Zur D; Yoshimi S; Freund KB; Peiretti E; Sarraf D
    Am J Ophthalmol; 2020 Sep; 217():104-113. PubMed ID: 32360342
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PHOTODYNAMIC THERAPY FOR SYMPTOMATIC SUBFOVEAL RETINAL PIGMENT EPITHELIAL DETACHMENT IN CENTRAL SEROUS CHORIORETINOPATHY: Outcomes and Prognostic Factors.
    Hwang S; Kang SW; Kim SJ; Jang JW; Kim KT
    Retina; 2019 Jun; 39(6):1117-1124. PubMed ID: 29517581
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fluorescein angiography as a primary guide for reduced-fluence photodynamic therapy for the treatment of chronic central serous chorioretinopathy.
    Koytak A; Bayraktar H; Ozdemir H
    Int Ophthalmol; 2020 Jul; 40(7):1807-1813. PubMed ID: 32274613
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Half-time photodynamic therapy in treatment of chronic central serous chorioretinopathy.
    Sheptulin V; Purtskhvanidze K; Roider J
    Graefes Arch Clin Exp Ophthalmol; 2018 Nov; 256(11):2027-2034. PubMed ID: 30097783
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Yellow (577 nm) micropulse laser versus half-dose verteporfin photodynamic therapy in eyes with chronic central serous chorioretinopathy: results of the Pan-American Collaborative Retina Study (PACORES) Group.
    Roca JA; Wu L; Fromow-Guerra J; Rodríguez FJ; Berrocal MH; Rojas S; Lima LH; Gallego-Pinazo R; Chhablani J; Arevalo JF; Lozano-Rechy D; Serrano M
    Br J Ophthalmol; 2018 Dec; 102(12):1696-1700. PubMed ID: 29439089
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantitative evaluation of damage to retinal capillaries caused by half-dose and half-time photodynamic therapy with optical coherent tomographic angiography.
    Xu F; Lai K; Zhou L; Huang C; Gong Y; Li L; Li C; Zhao H; Lu L; Jin C
    Photodiagnosis Photodyn Ther; 2021 Dec; 36():102477. PubMed ID: 34375777
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Half-dose photodynamic therapy followed by diode micropulse laser therapy as treatment for chronic central serous chorioretinopathy: evaluation of a prospective treatment protocol.
    Breukink MB; Mohr JK; Ossewaarde-van Norel A; den Hollander AI; Keunen JE; Hoyng CB; Boon CJ
    Acta Ophthalmol; 2016 Mar; 94(2):187-97. PubMed ID: 26670630
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: Predisposing Factors for Visual Acuity Outcomes.
    Matušková V; Vysloužilová D; Uher M
    Semin Ophthalmol; 2018; 33(5):690-699. PubMed ID: 29252091
    [TBL] [Abstract][Full Text] [Related]  

  • 36. One-year outcomes with half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy.
    Fujita K; Imamura Y; Shinoda K; Matsumoto CS; Mizutani Y; Hashizume K; Mizota A; Yuzawa M
    Ophthalmology; 2015 Mar; 122(3):555-61. PubMed ID: 25444637
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical characteristics of chronic central serous chorioretinopathy patients with insufficient response to reduced-settings photodynamic therapy.
    van Rijssen TJ; van Dijk EHC; Dijkman G; Boon CJF
    Graefes Arch Clin Exp Ophthalmol; 2018 Aug; 256(8):1395-1402. PubMed ID: 29732468
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A 50% vs 30% dose of verteporfin (photodynamic therapy) for acute central serous chorioretinopathy: one-year results of a randomized clinical trial.
    Zhao M; Zhang F; Chen Y; Dai H; Qu J; Dong C; Kang X; Liu Y; Yang L; Li Y; Zhou P; Pan CT; Zhang L; Liu P; Zhou H; Jiao X; Xiong Y; Tian R; Lu Y; Yu X; Li X
    JAMA Ophthalmol; 2015 Mar; 133(3):333-40. PubMed ID: 25555191
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long term outer retinal changes in central serous chorioretinopathy submitted to half-dose photodynamic therapy.
    Torres-Costa S; Penas S; Cerqueira AR; Brandão E; Carneiro Â; Rocha-Sousa A; Falcão-Reis F
    Photodiagnosis Photodyn Ther; 2021 Jun; 34():102235. PubMed ID: 33631379
    [TBL] [Abstract][Full Text] [Related]  

  • 40. One year outcome and predictors of treatment outcome in central serous chorioretinopathy: Multimodal imaging based analysis.
    Arora S; Maltsev DS; Singh Randhir S; Sahoo NK; Jhingan M; Parmeshwarappa D; Arora T; Kulikov A; Iovino C; Zur D; Fainberg G; Ibrahim MN; Tatti F; Gujar R; Venkatesh R; Reddy N; Snehith R; Peiretti E; Lupidi M; Chhablani J
    Eur J Ophthalmol; 2022 Jul; 32(4):2319-2327. PubMed ID: 34747194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.